RECOVERY Collaborative Group 2023, ' Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 401, no. 10387, pp. 1499-1507 . https://doi.org/10.1016/S0140-6736(23)00510-X
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
Postgraduate medicine, 133(6), 674-679. Taylor and Francis Ltd. Ginting, F, Sugianli, A K, Barimbing, M, Ginting, N, Mardianto, M, Kusumawati, R L, Parwati, I, de Jong, M D, Schultsz, C & van Leth, F 2021, ' Appropriateness of diagnosis and antibiotic use in sepsis patients admitted to a tertiary hospital in Indonesia ', Postgraduate medicine, vol. 133, no. 6, pp. 674-679 . https://doi.org/10.1080/00325481.2020.1816755
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
Sugianli, A K, Ginting, F, Parwati, I, de Jong, M D, van Leth, F & Schultsz, C 2021, ' Antimicrobial resistance among uropathogens in the Asia-Pacific region : a systematic review ', JAC-antimicrobial resistance, vol. 3, no. 1, dlab003, pp. dlab003 . https://doi.org/10.1093/jacamr/dlab003 JAC-Antimicrobial Resistance Sugianli, A K, Ginting, F, Parwati, I, de Jong, M D, van Leth, F & Schultsz, C 2021, ' Antimicrobial resistance among uropathogens in the Asia-Pacific region : A systematic review ', JAC-Antimicrobial Resistance, vol. 3, no. 1, dlab003 . https://doi.org/10.1093/jacamr/dlab003